3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
32
Neoplasm Metastasis
4
Metastatic Castration-Resistant Prostate Cancer
2
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Castration-resistant Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
1
Advanced Prostate Carcinoma
1
Interventions
enzalutamide
4
Abiraterone Acetate
2
radium Ra 223 dichloride
1
dactolisib
1
abiraterone
1
VT-464
1
Prednisone
1
NVP-BKM120
1
Flutamide
1
Crizotinib
1
Control Groups
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Castration-resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled